This clinical trial is being performed under the Best Pharmaceuticals for Children Act,
signed into law in 2002 in order to improve pediatric labeling for off-patent drugs. The
purpose of this study is to examine the efficacy and safety of lithium in the treatment of
pediatric patients with bipolar I disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)